Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Good morning.
Starting and sustaining a biotech company is never easy. If you need a reminder on that, read to the end of today’s newsletter.
BioAge’s bet on inflammation shows early promise BioAge is making its way into the race among drug companies to target inflammation as a way to treat chronic conditions. Continue to STAT+ to read the full story...
STAT News published a clinical update in Research Highlights on 21 Apr 2026.
The item focuses on STAT+: Kelonia Therapeutics’ road from floundering to $3 billion.
Review the original article for the full source wording and details.